Can Fite Biofarma (XTAE:CANF) 3-Year EBITDA Growth Rate : 45.80% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma 3-Year EBITDA Growth Rate?

Can Fite Biofarma's EBITDA per Share for the three months ended in Dec. 2023 was ₪-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 45.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 49.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 35.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Can Fite Biofarma was 55.50% per year. The lowest was -15.50% per year. And the median was 22.70% per year.

Competitive Comparison of Can Fite Biofarma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Can Fite Biofarma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's 3-Year EBITDA Growth Rate falls into.

Can Fite Biofarma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Can Fite Biofarma (XTAE:CANF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Can Fite Biofarma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).